Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BSBI-67003
- Development stage
- Preclinical
- Lead developer
- Baruch S. Blumberg Institute
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
BSBI-67003 is an orally available small molecule drug candidate under preclinical development for the treatment of yellow fever. Developed by the Baruch S. Blumberg Institute, the compound directly targets the yellow fever virus (YFV) nonstructural protein 4B (NS4B). By binding to NS4B, BSBI-67003 disrupts the structural integrity of endoplasmic reticulum-derived viral replication organelles (ROs) in infected cells, causing viral replication intermediates to leak into the cytoplasm and rapidly inhibiting nascent YFV RNA synthesis. Preclinical studies in hamster models have demonstrated potent, rapid-acting, and potentially Cmax-driven in vivo efficacy, providing significant protection against lethal infection even when administered at the peak of viremia.
Beyond the preview
Go deeper on BSBI-67003.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BSBI-67003.